A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
The DOI matches its Crossref record; 56 of the 59 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obsessive-compulsive disorder (OCD) is a common debilitating psychiatric illness that typically improves but does not remit with first-line medication and behavioral treatments. Serotonergic agents including selective serotonin reuptake inhibitors and clomipramine have provided the mainstay of OCD medication management for decades. Combined dopamine/serotonergic agents such as atypical antipsychotics are presently the only OCD-augmenting strategies proven effective via randomized controlled trials. Despite increasing evidence for a pathogenic role of glutamate in OCD, no controlled trials of glutamatergic augmenting agents have been reported. METHODS: An intent-to-treat sample included 44 subjects receiving standard treatment at the McLean/Massachusetts General Hospital Intensive Residential Treatment (IRT) program, 22 of whom also received memantine augmentation. Admission, monthly and discharge measures of OCD, depression, and psychosocial functioning were collected by raters blinded to augmentation status. Matched controls were selected based on sex, initial OCD severity, psychosocial functioning, and timing of admission. The Clinical Global Improvement Scale captured global clinical change. RESULTS: Mean (SD) Yale-Brown Obsessive Compulsive Scale score decreases were 7.2 (6.4) among the cases and 4.6 (5.9) among the matched controls, reflecting mean clinical improvement among the cases (27.0% decrease) but not the controls (16.5% decrease). Mean (SD) depression severity score decreases were 5.8 (9.5) among the cases and 4.7 (9.9) among the controls. Initial intrusive obsessions were significantly more severe among marked responders compared with limited response or nonresponse cases (4.4 vs 2.9; t = 2.15; P = 0.048). CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Future randomized double-blind placebo-controlled trials are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Memantine add-on to fluvoxamine significantly improved short-term outcomes in patients with moderate to severe OCD”
From The neurobiological link between OCD and ADHD (2014) · cites this paper as Stewart et al. 2010
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032 · cited 1×
“76, sensitivity of 100%, and specificity of 89% (using a cutoff score of 16).(22,40,41) The Obsessive-Compulsive Rating scale is a questionnaire-based measure that rates the severity of OCD symptom categories between 0 and 10.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799 · cited 1×
“67)(38) with excellent reliability.(38,39) The Y-BOCS checklist has more than 60 items organized into 2 miscellaneous categories and 13 other categories according to thematic content.”
BackgroundThe Work and Social Adjustment Scale: a simple measure of impairment in functioning
Mundt, J. C., Marks, I. M., Shear, M. K., & Greist, J. M. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.461 · Cited by 2,515 · cited 1×
“86, and increasing scores that reflect worse functional impairment.(43) The Clinical Global Impression (CGI) scale provides an assessment of overall impact of treatment rated between 1 (very much improved) and 7 (very much worse).”
BackgroundThe Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048 · cited 1×
“First-line OCD treatments, including selective serotonin reuptake inhibitors (SSRIs), cognitivebehavior therapy (CBT), and their combination, are effective in approximately 42% to 50%,(3) 62%, and 70% of cases, respectively.(4) However, symptoms often persist and full remission is uncommon with first-line approaches.”
BackgroundCortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852 · cited 1×
“Knockout mice for the striatum-expressed SAPAP3 gene, coding for a postsynaptic scaffolding protein at corticostriatal glutamatergic excitatory synapses, also developed facial lesions, repetitive grooming behaviors, and anxiety that were reversed with an SSRI and with gene replacement.(33) Memantine is a glutamate rec…”
BackgroundSynopsis of Psychiatry: 5th edn. Behavioral Sciences Clinical Psychiatry
Kaplan, H. I., & Sadock, B. J. (1989) · International Clinical Psychopharmacology · doi:10.1097/00004850-198907000-00008 · Cited by 852
Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder
Saxena, S., & Rauch, S. L. (2000) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70181-7 · Cited by 840 · cited 1×
“24 Moreover, glutamate receptor antagonism leads to an enhancement of 5-HT2A receptorYmediated transmission; 5-HT2A agonism leads to reduced glutamatergic transmission(24) and 5-HT receptor activation reduces the excitatory effect of glutamate on cellular activity.(50) It is this interaction that is believed to contri…”
BackgroundGlutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder
Arnold, P. D., Sicard, T., Burroughs, E., Richter, M. A., & Kennedy, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.769 · Cited by 357
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
Mataix-Cols, D., Rauch, S. L., Baer, L., Eisen, J. L., Shera, D. M., Goodman, W. K., Rasmussen, S. A., & Jenike, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.263 · Cited by 278 · cited 1×
“However, symptoms often persist and full remission is uncommon with first-line approaches.(5,6) When symptoms remain severe, a medication switch or use of augmenting agents may become necessary.”
BackgroundSelf-citationDickel, D. E., Veenstra-VanderWeele, J., Cox, N. J., Wu, X., Fischer, D. J., Van Etten-Lee, M., Himle, J. A., Leventhal, B. L., Cook, E. H., & Hanna, G. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.778 · Cited by 274
Denys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248 · cited 1×
“Switching from one SSRI to another benefits approximately 40% of OCD patients.(7) Although successful trials of atypical antipsychotics have demonstrated further symptom reduction, no controlled studies of glutamatergic agents as augmenting agents for standard OCD pharmacotherapy have yet been reported.”
BackgroundROSENBERG, D. R., MIRZA, Y., RUSSELL, A., TANG, J., SMITH, J. M., BANERJEE, S. P., BHANDARI, R., ROSE, M., IVEY, J., BOYD, C., et al. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000132812.44664.2d · Cited by 246
White Matter Abnormalities in Obsessive-compulsive Disorder: A Diffusion Tensor Imaging Study
Szeszko, P. R., Ardekani, B. A., Ashtari, M., Malhotra, A. K., Robinson, D. G., Bilder, R. M., & Lim, K. O. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.7.782 · Cited by 235
Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220
Arnold, P., Rosenberg, D., Mundo, E., Tharmalingam, S., Kennedy, J., & Richter, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1847-1 · Cited by 202
Multivariate Meta-Analysis of Controlled Drug Studies for Obsessive-Compulsive Disorder
Ackerman, D. L., & Greenland, S. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00012 · Cited by 202 · cited 1×
“However, symptoms often persist and full remission is uncommon with first-line approaches.(5,6) When symptoms remain severe, a medication switch or use of augmenting agents may become necessary.”
BackgroundLafleur, D. L., Pittenger, C., Kelmendi, B., Gardner, T., Wasylink, S., Malison, R. T., Sanacora, G., Krystal, J. H., & Coric, V. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0246-6 · Cited by 199
Geller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Farrell, C., Wagner, K. D., Emslie, G., & Carpenter, D. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322126313 · Cited by 187 · cited 1×
“Although subjects are atypical from those included in double-blinded randomized placebo-controlled trials, this study was designed to increase generalizability of its findings to individuals with severe OCD that warrants treatment augmentation.(47) From a research perspective, this study provides an additional line of…”
ResultSelf-citationAssociation of the SLC1A1 glutamate transporter gene and obsessive‐compulsive disorder
Stewart, S. E., Fagerness, J. A., Platko, J., Smoller, J. W., Scharf, J. M., Illmann, C., Jenike, E., Chabane, N., Leboyer, M., Delorme, R., et al. (2007) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30533 · Cited by 182
Self-citationfor the MEM-MD-29 Study Group, Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., & Gage, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.200 · Cited by 162 · cited 1×
“Nonetheless, memantine has reportedly been effective in a randomized placebo-controlled study of schizophrenia, another psychiatric illness in which white matter abnormalities have been implicated.(54) Limitations of this study must be acknowledged.”
BackgroundPorter, R. H. P., Eastwood, S. L., & Harrison, P. J. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01404-7 · Cited by 158
A diffusion tensor imaging study of white matter in obsessive–compulsive disorder
Cannistraro, P. A., Makris, N., Howard, J. D., Wedig, M. M., Hodge, S. M., Wilhelm, S., Kennedy, D. N., & Rauch, S. L. (2007) · Depression and Anxiety · doi:10.1002/da.20246 · Cited by 154
The Use of Aripiprazole in Obsessive-Compulsive Disorder: Preliminary Observations in 8 Patients
Connor, K. M., Payne, V. M., Gadde, K. M., Zhang, W., & Davidson, J. R. T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0107 · Cited by 135
Carlsson, M. L. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00146-9 · Cited by 132 · cited 10×
“Several lines of evidence implicate glutamatergic neurotransmission as a putative etiologic factor in OCD.21,22 Increased glutamate levels in cerebrospinal fluid,23 in the prefrontal and orbitofrontal cortex and in the striatum,24Y26 and reversible dysfunction in the glutamate-mediated corticostriatothalamic circuit26…”
BackgroundInfluentialYücel, M., Wood, S. J., Wellard, R. M., Harrison, B. J., Fornito, A., Pujol, J., Velakoulis, D., & Pantelis, C. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802050546 · Cited by 130
Van Ameringen, M., Mancini, C., Patterson, B., & Bennett, M. (2006) · Depression and Anxiety · doi:10.1002/da.20118 · Cited by 124
Pallanti, S., Quercioli, L., & Bruscoli, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1015 · Cited by 118
Pralong, É., Magistretti, P., & Stoop, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00017-5 · Cited by 116 · cited 1×
“It is this interaction that is believed to contribute to some mechanisms of psychiatric symptoms.(51) Given the previously reported white matter abnormalities and white matter volume decreases in OCD,(52,53) it could also be hypothesized that this is a direct or indirect product of cytotoxic damage.”
BackgroundShugart, Y. Y., Wang, Y., Samuels, J. F., Grados, M. A., Greenberg, B. D., Knowles, J. A., McCracken, J. T., Rauch, S. L., Murphy, D. L., Rasmussen, S. A., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30914 · Cited by 112
Li, X., May, R. S., Tolbert, L. C., Jackson, W. T., Flournoy, J. M., & Baxter, L. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0610 · Cited by 110
Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults
Stewart, S. E., Rosario, M. C., Baer, L., Carter, A. S., Brown, T. A., Scharf, J. M., Illmann, C., Leckman, J. F., Sukhodolsky, D., Katsovich, L., et al. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318172ef1e · Cited by 110 · cited 1×
“Interestingly, these symptoms and intrusive obsession symptoms are all represented in the Bsexual/ religious/aggressive/somatic/checking[ symptom dimension previously described in adult and child samples.(45,46) Given the cognitive benefits of memantine in Alzheimer’s disease, it could be postulated that this agent ma…”
BackgroundSelf-citationMemantine for Treatment-Resistant OCD
Poyurovsky, M., Weizman, R., Weizman, A., & Koran, L. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2191-a · Cited by 101 · cited 2×
“Memantine is a glutamate receptor antagonist that has been reported to reduce OCD symptoms in case studies of treatment-resistant individuals.(19,20,34,35) In this intent-to-treat, single-blinded, naturalistic case-control study, we examine the effectiveness of memantine as an augmenting agent to standard intensive re…”
BackgroundMemantine augmentation for refractory obsessive–compulsive disorder
Pasquini, M., & Biondi, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.013 · Cited by 100 · cited 2×
“Memantine is a glutamate receptor antagonist that has been reported to reduce OCD symptoms in case studies of treatment-resistant individuals.(19,20,34,35) In this intent-to-treat, single-blinded, naturalistic case-control study, we examine the effectiveness of memantine as an augmenting agent to standard intensive re…”
BackgroundBiological Approaches to Treatment-Resistant Obsessive-Compulsive Disorder
(2017) · Obsessive-Compulsive Disorder · doi:10.4324/9781315561073-31 · Cited by 97
Carlsson, M. L. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.102006401.x · Cited by 96
Stewart, S. E., Stack, D. E., Farrell, C., Pauls, D. L., & Jenike, M. A. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.01.004 · Cited by 94 · cited 1×
“More extensive details of this treatment program have been provided elsewhere.(36)”
BackgroundSelf-citationKoran, L. M., Gamel, N. N., Choung, H. W., Smith, E. H., & Aboujaoude, E. N. (2005) · PubMed · Cited by 91
Feusner, J. D., Kerwin, L. E., Saxena, S., & Bystritsky, A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4096 · Cited by 91 · cited 2×
“Memantine is a glutamate receptor antagonist that has been reported to reduce OCD symptoms in case studies of treatment-resistant individuals.(19,20,34,35) In this intent-to-treat, single-blinded, naturalistic case-control study, we examine the effectiveness of memantine as an augmenting agent to standard intensive re…”
BackgroundDelorme, R., Krebs, M.-O., Chabane, N., Roy, I., Millet, B., Mouren-Simeoni, M. C., Maier, W., Bourgeron, T., & Leboyer, M. (2004) · NeuroReport · doi:10.1097/00001756-200403220-00025 · Cited by 88
Mirtazapine for Obsessive-Compulsive Disorder
Koran, L. M., Gamel, N. N., Choung, H. W., Smith, E. H., & Aboujaoude, E. N. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0415 · Cited by 83
Outcome predictors for severe obsessive–compulsive patients in intensive residential treatment
Stewart, S. E., Yen, C.-H., Stack, D. E., & Jenike, M. A. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.08.007 · Cited by 80 · cited 1×
“These matching criteria were preliminarily established based on previous research at this program that identified OCD severity, psychosocial functioning, and sex as predictors of IRT outcome.(37)”
MethodSelf-citationSymptom Dimensions in Obsessive-Compulsive Disorder:Implications for theDSM-V
Leckman, J. F., Rauch, S. L., & Mataix‐Cols, D. (2007) · CNS Spectrums · doi:10.1017/s1092852900021179 · Cited by 73 · cited 1×
“Interestingly, these symptoms and intrusive obsession symptoms are all represented in the Bsexual/ religious/aggressive/somatic/checking[ symptom dimension previously described in adult and child samples.(45,46) Given the cognitive benefits of memantine in Alzheimer’s disease, it could be postulated that this agent ma…”
BackgroundBolton, J. M., Moore, G. J., MacMillan, S. N., STEWART, C. M., & Rosenberg, D. R. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200108000-00011 · Cited by 65 · cited 9×
“Several lines of evidence implicate glutamatergic neurotransmission as a putative etiologic factor in OCD.21,22 Increased glutamate levels in cerebrospinal fluid,23 in the prefrontal and orbitofrontal cortex and in the striatum,24Y26 and reversible dysfunction in the glutamate-mediated corticostriatothalamic circuit26…”
BackgroundInfluentialTopiramate plus paroxetine in treatment-resistant obsessive–compulsive disorder
Hollander, E., & Dell'Osso, B. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000199453.54799.cc · Cited by 60
Memantine as an Augmenting Agent for Severe Pediatric OCD
HEZEL, D. M., BEATTIE, K., & STEWART, S. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08091427 · Cited by 55
Self-citation(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1293 · Cited by 49
Buchsbaum, M. S., Hollander, E., Pallanti, S., Baldini Rossi, N., Platholi, J., Newmark, R., Bloom, R., & Sood, E. (2006) · Neuropsychobiology · doi:10.1159/000093342 · Cited by 40
Biological Approaches to Treatment-Resistant Obsessive-Compulsive Disorder
(1999) · Obsessive-Compulsive Disorder · doi:10.4324/9781410603241-23 · Cited by 29
The Neurobiology and Treatment of Obsessive–Compulsive Disorder
Swedo, S. E., & Grant, P. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199798261.003.0042 · Cited by 16
Trazodone Augmentation in OCD: A Case Series Report
Marazziti, D., Gemignani, A., & Dell'Osso, L. (1999) · CNS Spectrums · doi:10.1017/s1092852900006817 · Cited by 14
[Significance of the glutaminergic system for obsessive-compulsive disorder].
Nissen, J. B., & Thomsen, P. H. (2008) · PubMed · Cited by 2
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Adjunctive lamotrigine [799,800] 2 Adjunctive memantine [622,781-783] 2”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…obsessive-compulsive disorder include monotherapy with once-weekly morphine [I (PCT)] (Koran et al., 2005); and the glutamate-modulating compounds riluzole [III] (Coric et al., 2005; Pittenger et al., 2008), memantine [III] (Stewart et al., 2010), and glycine [I (PCT)(Greenberg et al., 2009).”
BackgroundPittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“…below, genetic studies have suggested an association between polymorphisms in the NMDA NR2B subunit and OCD risk (Arnold et al., 2004), and early pharmacological studies with the NMDA-blocking drug memantine have shown promise (Aboujaoude et al., 2009; Feusner et al., 2009; Stewart et al., 2010).”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
“…and memantine) have been shown to ameliorate OCD symptoms in open (Aboujaoude et al , 2009; Coric et al , 2005; Feusner et al , 2009; Lafleur et al , 2006; Pittenger et al , 2011; Rodriguez et al , 2010; Stewart et al , 2010) and controlled trials (Afshar et al , 2012; Ghaleiha et al , 2013).”
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Metadata
- Authors
- Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A.
- Affiliations
- Harvard University (US)
- McLean Hospital (US)
- Tufts University (US)
- Corresponding author
- Stewart, S. Evelyn
- Jenike, Eric A.
- Hezel, Dianne M.
- Stack, Denise Egan
- Jenike, Michael A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2010-02
- Volume
- 30
- Issue
- 1
- Pages
- 34-39
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2056828397
- Cited by
- 158
- References
- 59
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 2 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 11 · 2014: 13 · 2013: 18 · 2012: 14
- FWCI
- 21.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- memantine, obsessive-compulsive disorder, drug augmentation, depression severity, Yale-Brown Obsessive Compulsive Scale, treatment response
- MeSH terms
- Adult, Benzodiazepines, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Inpatients, Male, Memantine, Obsessive-Compulsive Disorder, Residential Facilities, Antipsychotic Agents, Case-Control Studies, Single-Blind Method, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.